skip to Main Content

Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route

Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route
Macarulla et al1 have recently reported the results of a phase I/II trial (NAB-Paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer [FRAGANCE]) that explored the safest and most effective dose and schedule of gemcitabine plus nanoparticle albumin-bound (NAB) paclitaxel (Gem-NAB) in patients with previously untreated, locally advanced and metastatic pancreatic cancer …

Read more . . .


Back To Top